Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase I/II study of cevostamab in relapsed/refractory multiple myeloma previously exposed to BCMA-targeted therapy
MOH_2022-12-01_011852Phase 2Not yet recruiting
- Sponsor
- Roche Pharmaceuticals Israel
- Start
- Nov 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cevostamab in multiple myeloma (MM) (2 cohorts), sponsored by Roche Pharmaceuticals Israel. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
cevostamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2022-12-01_011852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-12-01_011852.